Hong Kong Reproductive Medicine Specialist Centre Success Rate: Influencing Factors and Data Interpretation

Opening: Real Consultation Scenario

"Doctor, what exactly is your centre's success rate? My friend did it at another clinic and said they achieved over 60%. What are your numbers?" — This is a conversation that occurs almost daily in reproductive medicine clinics. A 38-year-old woman with an AMH of 1.2 ng/mL and bilateral tubal blockage, holding test reports from another hospital, speaks rapidly, her eyes filled with anxiety and an urgent need for comparison. What she needs is not a vague number, but a meaningful answer that corresponds to her specific situation.

====== Module A: Direct Answer to the Question ======

Success Rate is Not a Single Number, but a Set of Conditional Probabilities

The success rate data of Hong Kong Reproductive Medicine Specialist Centres typically uses the live birth rate per embryo transfer cycle or the cumulative live birth rate per egg retrieval cycle as core indicators. According to public data from the Hong Kong Council on Human Reproductive Technology (the equivalent of the HFEA) and annual reports from various centres, for women under 35, the live birth rate per transfer cycle is approximately 45%–55%; for ages 35–38, it's about 35%–45%; for ages 39–41, about 20%–30%; and for those over 42, about 10%–18%. However, these figures only provide personalised reference value when combined with the patient's age, ovarian reserve, sperm quality, embryo chromosomal euploidy, uterine cavity environment, and the centre's laboratory quality control standards.

A reasonable way to directly answer "What is the success rate?" is: For a specific patient, the success rate = the live birth rate of a comparable population at that centre ± individual deviation. Centres in Hong Kong publish data stratified by age. Patients should request to see the live birth rates for their specific age group and diagnostic category, rather than a general "clinical pregnancy rate."

====== Module C: The Doctor's Perspective ======

How Doctors Define and Evaluate Success Rates

When discussing success rates, reproductive medicine doctors focus not on a single number, but on three dimensions:

• Biological Success Rate: Oocyte maturation rate, fertilisation rate, blastocyst formation rate, embryo euploidy rate. These indicators reflect the laboratory culture system and embryo developmental potential.
• Clinical Success Rate: Biochemical pregnancy rate, clinical pregnancy rate (fetal heartbeat at 6 weeks), ongoing pregnancy rate (after 12 weeks), live birth rate. The live birth rate is the gold standard.
• Patient-Adaptive Success Rate: Whether the cumulative live birth rate improves for the same patient after adjusting the stimulation protocol or transfer strategy.

Doctors will explain to patients: "Based on your current AMH, antral follicle count, age, and previous embryo history, for similar patients in our centre, the live birth rate per euploid blastocyst transfer is approximately 50%–60%. However, this assumes the embryo has passed PGT-A screening. If you choose an unscreened blastocyst, the live birth rate decreases by about 10–15 percentage points." This condition-based answer is the clinically meaningful way to communicate success rates.

====== Module D: Differences Across Age Groups ======

Age is the Most Critical Stratifying Variable for Success Rate

Female age directly affects the oocyte chromosomal aneuploidy rate. The following data is compiled from the annual reports (2019–2023) of several Hong Kong reproductive medicine centres, calculated as the proportion of cycles resulting in a live birth per egg retrieval cycle:

Age Group	Live Birth Rate per Transfer Cycle (%)	Cumulative Live Birth Rate per Egg Retrieval Cycle (%)	Proportion of Euploid Embryos (%)
< 35 years	45% — 55%	55% — 68%	55% — 65%
35 — 37 years	38% — 46%	45% — 58%	40% — 52%
38 — 40 years	25% — 35%	32% — 44%	28% — 38%
41 — 42 years	15% — 22%	20% — 30%	15% — 25%
> 42 years	8% — 15%	10% — 20%	8% — 15%

Note: Data sourced from the Hong Kong Council on Human Reproductive Technology annual statistics and public reports from some centres. Due to differences in patient selection criteria, data may fluctuate by 5–8 percentage points between centres. Cumulative live birth rates include frozen embryo transfer cycles.

The table clearly shows that age 35 is a significant turning point. After 35, the proportion of euploid embryos decreases by about 8–10 percentage points every two years, directly lowering the live birth rate. For patients over 42, even with PGT-A screening, the live birth rate rarely exceeds 20%, primarily limited by the number of available euploid embryos.

====== Module F: Differences Between Centres ======

Differences in Success Rates Among Hong Kong Reproductive Medicine Centres

Hong Kong currently has over 10 licensed reproductive medicine centres, affiliated with public hospitals, private hospitals, and specialist clinics. These centres differ in the following aspects, which in turn affect success rates:

• Laboratory Hardware and Quality Control Systems: Differences in configurations such as time-lapse embryo monitoring systems, low-oxygen incubators, microfluidic sperm sorting, and PGT-A technology platforms (NGS vs. aCGH). Centres equipped with advanced real-time monitoring systems typically have blastocyst formation rates 5–10% higher.
• Embryologist Experience: Some embryologists in Hong Kong have over 20 years of experience in ICSI and blastocyst culture, achieving vitrification thaw survival rates of over 98%, while less experienced teams may achieve around 95%.
• Patient Selection Strategies: Some private centres are more accepting of older patients, those with low AMH, or those with repeated failure, which can lower their overall success rate data. This does not indicate inferior technology but rather a different patient demographic.
• Differences in Transfer Strategies: Some centres prefer single blastocyst transfer + PGT-A, while others opt for double blastocyst transfer based on patient preference. The live birth rate per transfer cycle for single embryo transfer may be slightly lower, but the multiple pregnancy and miscarriage rates are lower, and the cumulative live birth rate may actually be higher.

When comparing success rates between centres, you must request subgroup data that matches your age, diagnosis, and embryo screening strategy. A general "60% success rate" derived from a population of oocyte donors under 35 is meaningless for a 40-year-old patient using her own eggs.

====== Module G: Easiest Details to Overlook ======

Four Easily Overlooked Factors Affecting Success Rates

① The Hidden Deduction of Miscarriage Rate from "Success Rate"

Many centres report a "clinical pregnancy rate" that includes cases with a fetal heartbeat at 6 weeks, but approximately 12%–18% of these will miscarry naturally before 12 weeks. Therefore, the clinical pregnancy rate is usually 8–15 percentage points higher than the live birth rate. Patients should request to see the "ongoing pregnancy rate" or "live birth rate," as these indicators are closer to the final outcome.

② Whether Frozen Embryo Transfer Cycles are Included in the Denominator

Some centres only report the "live birth rate per transfer cycle," ignoring cycles cancelled due to having no embryos to transfer. If 20% of egg retrieval cycles fail to result in a transfer due to poor egg quality or fertilisation failure, the live birth rate per egg retrieval cycle will be significantly lower than the per-transfer data. A more objective indicator is the "cumulative live birth rate per initiated cycle."

③ The Loss of Embryo Viability Due to Biopsy

After PGT-A biopsy, the embryo thaw survival rate is approximately 94%–98%, meaning about 2%–6% of embryos do not survive the biopsy. For patients with only 1–2 blastocysts, the risk associated with biopsy is proportionally higher. The decision to undergo PGT-A requires weighing the loss from biopsy against the benefit of screening.

④ The Weight of Male Factors in Success Rates

Severe oligoasthenoteratozoospermia, sperm DNA fragmentation index (DFI) exceeding 30%, or Y chromosome microdeletions can significantly reduce blastocyst formation and euploidy rates. However, most success rate data is not stratified by male factors. If the male partner's DFI is high, you should request success rate data from the centre specifically for patients with similar male factor issues.

====== Module L: Interpretation of Key Tests ======

Key Diagnostic Indicators Related to Success Rate

The following indicators are used to predict individual success rates and help doctors and patients jointly decide on a treatment path:

Indicator	Reference Range	Impact on Success Rate
AMH (Anti-Müllerian Hormone)	≥1.2 ng/mL (Normal) 0.5–1.1 ng/mL (Low) <0.5 ng/mL (Very Low)	For every 1 ng/mL decrease in AMH, the number of eggs retrieved decreases by 2–3, and the cumulative live birth rate decreases by approximately 8–12%. When AMH <0.5, the live birth rate per egg retrieval cycle is usually <10%.
FSH (Follicle-Stimulating Hormone)	<10 IU/L (Normal) 10–15 IU/L (Borderline) >15 IU/L (Elevated)	FSH >12 IU/L indicates diminished ovarian reserve, potentially poor response to stimulation medications, fewer eggs retrieved, and a correspondingly lower success rate.
Antral Follicle Count (AFC)	≥8 (both ovaries combined)	When AFC <5, the number of eggs retrieved is usually ≤4, and the probability of forming a transferable embryo decreases by more than 50%.
Sperm DNA Fragmentation Index (DFI)	<15% (Normal) 15–30% (Moderate) >30% (High)	When DFI >30%, the blastocyst formation rate decreases by about 20%, and the miscarriage rate increases by 1.5–2 times.
Vitamin D	30–50 ng/mL	Vitamin D deficiency (<20 ng/mL) is associated with an approximately 8–10% reduction in embryo implantation rate, which can improve with supplementation.

These indicators should not be used in isolation but interpreted comprehensively. For example, a patient with AMH 0.8 ng/mL but AFC 7 and FSH 8 IU/L may still achieve 6–8 eggs, resulting in a better success rate than a patient with the same AMH but an AFC of only 3.

====== Module N: Special Situations ======

Success Rate Assessment in Special Situations

Recurrent Implantation Failure (RIF)

For patients who have not conceived after three consecutive transfers of good-quality embryos, investigations should include endometritis, chronic endometritis, endometrial receptivity, embryo chromosomal abnormalities, and immune factors. After identifying and treating the specific cause, the live birth rate can recover to 18%–30%, but this is still significantly lower than for first-time IVF patients. Some centres in Hong Kong offer multidisciplinary consultations for recurrent failure, providing a more systematic evaluation for these patients.

Poor Ovarian Reserve (POR)

For patients with AMH <0.5 ng/mL or AFC <3, the live birth rate per egg retrieval cycle is approximately 5%–12%. These patients need to discuss options like natural cycles, mild stimulation, or follicle wave protocols, and prepare for accumulating embryos over multiple cycles. A single-cycle success rate number is almost meaningless for POR patients; a cumulative strategy is key.

Adenomyosis/Fibroids

Submucosal fibroids and intramural fibroids (compressing the endometrium) can reduce implantation rates by about 15%–25%. Patients with adenomyosis have a higher risk of early pregnancy miscarriage. Surgical treatment of the lesions can improve the live birth rate, but the surgery itself may have potential impacts on ovarian function, requiring individualised decision-making.

====== Module Q: Frequently Asked Questions ======

Common Questions About Success Rates

• "Why does one centre claim a 65% success rate while another says 50%?" — This could be due to differences in patient demographics, denominator definitions (per transfer vs. per egg retrieval), or whether donor egg cycles are included. Always ask for live birth rates stratified by age and diagnosis.
• "Can PGT-A improve the success rate?" — For older patients (≥38 years) or those with recurrent miscarriage, PGT-A screening for euploid embryos can increase the live birth rate per single transfer by about 10–18%, but it does result in the loss of some embryos. It is not routinely recommended for women under 35 without genetic risks.
• "What is the difference in success rates between Hong Kong public hospitals and private centres?" — Public hospital patients tend to be older and have more complex diagnoses, so their overall live birth rate may be 5–10% lower than private centres, but the cost is only one-third to one-half. The choice depends on your individual circumstances.
• "Which has a higher success rate: frozen or fresh embryo transfer?" — For patients at risk of ovarian hyperstimulation syndrome or with elevated progesterone, frozen embryo transfer has a higher live birth rate. For other patients, the live birth rates are similar between the two strategies, but frozen cycles offer more flexibility.

====== Module R: Practitioner's Observation ======

Practitioner's Observation: How Success Rate Data is Really Used

Coordinators and doctors with over 10 years of experience in reproductive medicine will tell you: Success rates are a reference for decision-making, not a promise, nor a competitive benchmark. A nurse involved in patient education mentioned: "We've seen a patient with an AMH of only 0.4 who, after three cycles of mild stimulation, finally got one euploid blastocyst and successfully delivered. We've also seen a 35-year-old with normal AMH who failed three transfers. Individual variation is far greater than group data."

Reproductive medicine centres in Hong Kong typically provide an individualised prognosis report during the initial consultation, which includes a success rate prediction based on the centre's own data model. This report usually lists the following conditions:

• Baseline live birth rate corresponding to your current age
• Estimated number of eggs retrieved adjusted for AMH and AFC
• Expected number of euploid embryos (based on age and previous embryo history)
• The minimum number of egg retrieval cycles needed to achieve a 50% cumulative live birth probability

This model-based individualised prognosis is far more clinically valuable than any single success rate percentage. Patients should proactively request such a quantitative assessment from the centre, rather than settling for a single percentage.

====== Conclusion: Doctor's Advice ====== ====== Risk Reminder ======